

## **MiMedx® Selects Allen & Caron for Investor Relations, Media Relations and Corporate Communications**

April 30, 2012 5:37 PM ET

### **MIMEDX® SELECTS ALLEN & CARON FOR INVESTOR RELATIONS, MEDIA RELATIONS AND CORPORATE COMMUNICATIONS**

**Kennesaw, GA (April 30, 2012)** ... MiMedx Group, Inc (OTCBB:MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has selected Allen & Caron Inc., with offices in New York City, Irvine CA and London, as its agency for investor relations and corporate communications. Allen & Caron will develop an outreach program to increase visibility in the investment community and business/financial media.

MiMedx Chairman and CEO Parker H. "Pete" Petit commented, "We believe that the rapid increase in physicians utilizing the product dictates that MiMedx Group should be properly introduced to institutional investors both domestically and abroad. We believe that 2012 will continue to demonstrate very rapid revenue growth as we announce significant clinical results, including randomized controlled trials, and additional reimbursement successes for private pay as well as Medicare. Our unique amniotic membrane allografts are proving to be a very cost effective and clinically effective addition to many medical procedures.

Mr. Petit said, "We selected Allen & Caron because of their premier reputation and experience with rapidly growing healthcare firms. We interviewed a number of investor relations firms prior to making our selection. I am certain they will become an excellent partner in helping us add institutional investors to our existing investor base of high net worth individuals."

Allen & Caron Chairman and CEO Joseph Allen said, "Innovative healthcare companies with strong doctor and patient benefits are one of the best kinds of companies to work with in our business. When they win, everybody wins. MiMedx is a perfect example of that type of company. Their EpiFix® and AmnioFix® products address a broad range of uses that comprise wound care, burn healing, soft tissue trauma, nerve and tendon repair, spinal applications and sports medicine. We believe that as these products find their audiences the rate of growth at MiMedx will continue to accelerate – although the revenue growth rate is already very high indeed."

#### **About MiMedx Group**

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 70,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.